Article and Video CATEGORIES
Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.
November is Lung Cancer Awareness Month. What are you grateful for?
Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.
[powerpress]
Get more information about the TH4000 Trial.
[ratingwidget post_id=0]
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi Caregiver and welcome to Grace. I'm sorry that you need to be here and hope we can help. Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...
Hi Bob, Welcome to Grace. I'm sorry about your sil. Unfortunately, cancer becomes resistant to TKIs like tagrisso. Sometimes all of the cancer becomes resistant at once and sometimes just parts...
Hi Kimberly, Welcome to Grace. I'm sorry you are here and glad you've found us.
It sounds like a biopsy would be the next step. I can't speak to what...